Overview

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal reflux disease (GERD).
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Dexlansoprazole
Lansoprazole